利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

39 条记录 (耗时 0.016 秒)

    VASCULAR DILATORS
    1.
    发明申请
    VASCULAR DILATORS 审中-公开
    血管扩张器

    公开(公告)号：WO2015057573A1

    公开(公告)日：2015-04-23

    申请号：PCT/US2014060270

    申请日：2014-10-13

    申请人： US OF AMERICA AS REPRESENTED BY THE SEC DEP OF HEALTH & HUMAN SERVICES ,  FORD HENRY HEALTH SYSTEM

    发明人： LEDERMAN ROBERT JAY ,  KOCATURK OZGUR ,  GREENBAUM ADAM BRETT

    IPC分类号： A61M29/00 ,  A61M25/01 ,  A61M25/04

    CPC分类号： A61M29/00 ,  A61B17/00234 ,  A61B17/3478 ,  A61B2017/00247 ,  A61B2017/00336 ,  A61M25/0662

    摘要： Technology disclosed herein provides a reduced transition between the edge of a rigid vascular dilator and the distal edge of the accompanying introducer sheath. Disclosed dilators can be segmented into two or more primarily longitudinally extending parts, can have rigid circumferential or semi-circumferential leading shoulders to minimize the transition between the dilator and the sheath edge, and can contain internal recesses to allow sequential retraction of segments once the introducer sheath is delivered to a target chamber. With this technology, vascular introducer sheaths can be introduced percutaneously into a broad range of diseased target vessels and chambers with reduced damage to the wall of the vessel or chamber, and with reduced damage to the distal end of the introducer sheath.

    摘要翻译： 本文公开的技术提供刚性血管扩张器的边缘和伴随的引导器护套的远端边缘之间的减小的过渡。 所公开的扩张器可以分成两个或更多个主要纵向延伸的部分，可以具有刚性的圆周或半圆周的前肩，以使扩张器和护套边缘之间的过渡最小化，并且可以包含内部凹槽，以允许在导引器 鞘被输送到目标室。 通过这种技术，血管引导器护套可以经皮引入广泛的患病目标血管和腔室，对容器或腔室壁的损伤减小，同时对引导器护套远端的损伤减少。

    COOLING SYRINGE AND METHOD FOR INDUCING SELECTIVE HYPOTHERMIA OF A BODY TISSUE DURING MINIMALLY INVASIVE SURGERY
    2.
    发明申请
    COOLING SYRINGE AND METHOD FOR INDUCING SELECTIVE HYPOTHERMIA OF A BODY TISSUE DURING MINIMALLY INVASIVE SURGERY 审中-公开
    用于诱导微创外科手术中身体组织选择性上皮的冷却注射器和方法

    公开(公告)号：WO2014052406A9

    公开(公告)日：2014-11-27

    申请号：PCT/US2013061606

    申请日：2013-09-25

    申请人： FORD HENRY HEALTH SYSTEM

    发明人： ROGERS CRAIG GLENN ,  JEONG WOOJU ,  MENON MANI

    IPC分类号： A61B18/02 ,  A61B17/34 ,  A61M5/178 ,  A61M37/00

    CPC分类号： A61F7/12 ,  A61B34/30 ,  A61F2007/0059 ,  A61F2007/0288

    摘要： A cooling syringe and method are provided for inducing selective hypothermia of a body tissue during minimally invasive surgery. The cooling syringe includes an elongated, hollow housing configured to receive a cooling substance, the housing having a proximal end and a distal end. An actuator is at least partially received within the housing, the actuator including an elongated shaft having a proximal end and a distal end. The actuator includes a handle portion at the shaft proximal end and an end cap received on the shaft distal end, the shaft and end cap together forming a plunger. A guidance cap having a central channel is received on the shaft and disposed at a proximal end thereof. The actuator is movable with respect to the guidance cap and within the housing to dispense the cooling substance from the housing distal end.

    摘要翻译： 提供了一种冷却注射器和方法，用于在微创手术中诱导身体组织的选择性低体温。 冷却注射器包括构造成接收冷却物质的细长的中空壳体，该壳体具有近端和远端。 致动器至少部分地容纳在壳体内，致动器包括具有近端和远端的细长轴。 致动器包括在轴近端处的手柄部分和容纳在轴远端的端盖，所述轴和端盖一起形成柱塞。 具有中心通道的引导帽被容纳在轴上并设置在其近端。 致动器可相对于引导帽并在壳体内移动以从壳体远端分配冷却物质。

    NITRIC OXIDE DONORS FOR TREATMENT OF DISEASE AND INJURY
    6.
    发明申请
    NITRIC OXIDE DONORS FOR TREATMENT OF DISEASE AND INJURY 审中-公开
    用于治疗疾病和伤害的硝酸氧化物

    公开(公告)号：WO03056899A9

    公开(公告)日：2004-04-15

    申请号：PCT/US0300323

    申请日：2003-01-06

    申请人： FORD HENRY HEALTH SYSTEM ,  CHOPP MICHAEL

    发明人： CHOPP MICHAEL

    IPC分类号： C07D487/04 ,  A61K31/00 ,  A61K31/519 ,  A61K45/00 ,  A61P9/00 ,  A61P9/04 ,  A61P9/10 ,  A61P25/00 ,  A61P25/14 ,  A61P25/28 ,  A61P43/00 ,  C12N5/08 ,  A61K31/505

    CPC分类号： A61K31/519 ,  A61K31/00

    摘要： A method of promoting neurogenesis by administering a therapeutic amount of a phosphodiesterase inhibitor compound to a patient in need of neurogenesis promotion. A compound for providing neurogenesis having an effective amount of a phosphodiesterase inhibitor sufficient to promote neurogenesis. A phosphodiesterase inhibitor for promoting neurogenesis. A method of augmenting the production of brain cells and facilitating cellular structural and receptor changes by administering an effective amount of a phosphodiesterase inhibitor compound to a site in need of augmentation. A method of increasing both neurological and cognitive function by administering an effective amount of a phosphodiesterase inhibitor compound to a patient.

    摘要翻译： 一种通过向需要神经发生促进的患者施用治疗量的磷酸二酯酶抑制剂化合物来促进神经发生的方法。 一种用于提供神经发生的化合物，其具有足以促进神经发生的有效量的磷酸二酯酶抑制剂。 用于促进神经发生的磷酸二酯酶抑制剂。 通过向需要增加的部位施用有效量的磷酸二酯酶抑制剂化合物来增加脑细胞的产生并促进细胞结构和受体变化的方法。 通过向患者施用有效量的磷酸二酯酶抑制剂化合物来增加神经学和认知功能的方法。

    INHIBITION OF PROTEIN-PHOSPHATASES FOR THE TREATMENT OF HEART FAILURE
    7.
    发明申请
    INHIBITION OF PROTEIN-PHOSPHATASES FOR THE TREATMENT OF HEART FAILURE 审中-公开
    用于治疗心力衰竭的蛋白质磷酸酶的抑制

    公开(公告)号：WO02056837A3

    公开(公告)日：2003-03-06

    申请号：PCT/US0200957

    申请日：2002-01-15

    申请人： FORD HENRY HEALTH SYSTEM ,  GUPTA RAMESH C ,  SABBAH HANI N

    发明人： GUPTA RAMESH C ,  SABBAH HANI N

    IPC分类号： A61K38/00 ,  A61K38/17 ,  A61P9/10 ,  C07K14/47 ,  C12N15/57 ,  C12P21/08 ,  C12N9/16 ,  A61K38/46 ,  A61K39/00 ,  C07K1/00

    CPC分类号： A61K38/1709 ,  A61K38/005 ,  C07K14/4703

    摘要： There is provided a method for treating an individual with cardiovascular disease, including the step of administering a therapeutically effective amount of protein phosphatase inhibitor and analogues thereof, to the individual after the onset of cardiac ischemia. Also provided is a method of treating an individual with cardiovascular disease by selectively inhibiting protein phosphatase activity in the heart. A composition for the treatment of heart failure, the composition including an inhibitor of PP1 and a pharmaceutically acceptable carrier is also provided. There is provided a sequence encoding inhibitor-2.

    摘要翻译： 提供了治疗患有心血管疾病的个体的方法，包括在心脏缺血发作后向个体施用治疗有效量的蛋白质磷酸酶抑制剂及其类似物的步骤。 还提供了通过选择性抑制心脏中的蛋白磷酸酶活性来治疗患有心血管疾病的个体的方法。 还提供了用于治疗心力衰竭的组合物，包含PP1抑制剂和药学上可接受的载体的组合物。 提供了编码抑制剂-2的序列。

    APPARATUS AND METHOD FOR CAPSULE FORMATION IN TISSUE
    9.
    发明申请
    APPARATUS AND METHOD FOR CAPSULE FORMATION IN TISSUE 审中-公开
    用于组织中胶囊形成的装置和方法

    公开(公告)号：WO2010028310A3

    公开(公告)日：2010-06-24

    申请号：PCT/US2009056129

    申请日：2009-09-04

    申请人： AHMANN FRANK ,  SABBAH HANI N ,  SHANNON DONALD ,  CARDIOPOLYMERS INC ,  FORD HENRY HEALTH SYSTEM

    发明人： AHMANN FRANK ,  SABBAH HANI N ,  SHANNON DONALD

    IPC分类号： A61F2/958 ,  A61M25/06

    CPC分类号： A61M25/1029 ,  A61B17/7097 ,  A61B2090/3966 ,  A61F2/0059 ,  A61F2/12 ,  A61F5/0036 ,  A61L31/04 ,  A61L31/14 ,  A61L31/146 ,  A61M25/1027 ,  A61M2025/0089 ,  A61M2025/1054

    摘要： Capsules, emplacement apparatus, and associated methods for establishing a capsule within tissue are described herein. The emplacement apparatus may be catheter-based or implemented in a handheld unit. The emplacement apparatus serves to introduced an encapsulating membrane in a collapsed condition into the tissue, and then to expand the encapsulating membrane within the tissue into a capsule by injection of fill material into the encapsulating membrane. Other than being capable of injection through the emplacement apparatus, the fill material may be selected and formulated to achieve such mechanical and biological properties within the encapsulating membrane after injection as are desired to achieve the therapeutic effect sought for the patient. Mechanically, the fill material within the encapsulating membrane after injection may be a liquid, a semi-solid such as a gel, or a solid such as a cross-linked polymer. The fill material may or may not be sealed within the encapsulating membrane.

    摘要翻译： 本文描述了用于在组织内建立胶囊的胶囊，置换装置和相关方法。 移植装置可以是基于导管的或在手持单元中实现的。 放置装置用于将处于折叠状态的封装膜引入组织中，然后通过将填充材料注入到包封膜中将包封膜在组织内膨胀成胶囊。 除了能够通过放置装置注射之外，可以选择和配制填充材料以在注射之后在包封膜内实现如实现对患者所寻求的治疗效果所希望的这样的机械和生物学特性。 在机械上，注射后的包封膜内的填充材料可以是液体，半固体如凝胶，或诸如交联聚合物的固体。 填充材料可以或可以不被密封在封装膜内。

    COLLAGEN-DERIVED PEPTIDE AS BIOMARKER, THERAPEUTIC AGENT AND TARGET
    10.
    发明申请
    COLLAGEN-DERIVED PEPTIDE AS BIOMARKER, THERAPEUTIC AGENT AND TARGET 审中-公开
    胶原衍生肽作为生物标志物，治疗药物和目标

    公开(公告)号：WO2009111471A3

    公开(公告)日：2009-12-30

    申请号：PCT/US2009035876

    申请日：2009-03-03

    申请人： FORD HENRY HEALTH SYSTEM ,  WU WILLIAM

    发明人： WU WILLIAM

    IPC分类号： G01N33/53 ,  A61K38/00

    CPC分类号： G01N33/57415 ,  G01N33/57434 ,  G01N2333/78

    摘要： Some embodiments comprise a novel peptide derived from Type 1 collagen which is a potent activator of ECM synthesis and remodeling and which may facilitate the detection and/or assessment of the presence of tumor cells, or other cells of interest, by detecting or assessing the presence of the peptide and/or its subfragments, and which may stimulate the production of proteases in a subject.

    摘要翻译： 一些实施方案包括衍生自1型胶原的新型肽，其是ECM合成和重塑的有效激活剂，并且其可以通过检测或评估存在的肿瘤细胞或其它感兴趣的细胞来检测和/或评估肿瘤细胞或其它细胞的存在 的肽和/或其亚片段，并且其可以刺激受试者中蛋白酶的产生。